Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452528 · ClinicalTrials.gov registry record · Phase 2
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02452528: Clinical Trial Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
NCT02452528 is a Phase 2 study that was terminated before completion, run by Arrowhead Pharmaceuticals. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452528, a Phase 2 study, was terminated before completion, sponsored by Arrowhead Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
Interventions
- DRUG Placebo
- DRUG Tenofovir
- DRUG Entecavir
- DRUG diphenhydramine
- DRUG ARC-520
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Why NCT02452528 stopped before completion
NCT02452528 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02452528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02452528 about?
NCT02452528 is a clinical study titled "Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus". Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination with entecavir or tenofovir and be evaluated for safety and efficacy.
What is the current status of trial NCT02452528?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02452528?
The interventions under investigation include: Placebo (DRUG), Tenofovir (DRUG), Entecavir (DRUG), diphenhydramine (DRUG), ARC-520 (DRUG).
Who is sponsoring clinical trial NCT02452528?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02452528's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia